Company / FCF Margin
Nurix Therapeutics, Inc. FCF Margin History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-313.7%
FY2025
5-year range
-333.4% / -3.4%
FY2021-FY2025
Trend
+5.9%
vs FY2024
Sector context
#105 of 133
Health Care
What the data says
Nurix Therapeutics, Inc.'s fcf margin of -313.7% is lower than 79% of companies in the Health Care sector (FY2025). FCF Margin has fluctuated over the past 7 years, ranging from -333.4% in FY2024 to -3.4% in FY2021.
Based on SEC 10-K filings.
-313.7% in FY2025 with a 5-year CAGR of -287.7%.
Declined from -116.6% to -313.7% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -11.1pp
- 5-Year Change
- -287.7pp
- 10-Year Change
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 133This company -313.7% Sector average -632.8%
▼
+50.4% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 5.9% year-over-year.
- Currently 319.1pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2021.
- Lowest fcf margin in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -313.7% | +5.9% |
| FY2024 | -333.4% | -185.9% |
| FY2023 | -116.6% | +61.5% |
| FY2022 | -302.6% | -8879.5% |
| FY2021 | -3.4% | +87.0% |
| FY2020 | -26.0% | -671.5% |
| FY2019 | -3.4% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026